Combination CPI targeting PD-1 and CTLA-4 appears to increase clinical benefit in some tumor types2,10–12; however, the addition of anti-CTLA-4 complicates therapy with increased toxicity13, and a large proportion of patients still do not benefit. Here, PDCD1 is linked to neoplasm.